Corcept Therapeutics Corp (CORT) - Long-Term Debt to Capital Coefficient

Corcept Therapeutics Corp - graphic logo of issuer CORT

The Corcept Therapeutics (CORT) market price chart demonstrates the asset's dynamics, with a metric of 0.01. The company's finances are fueled by demand for its Cushing's disease treatment, creating a steady cash flow. The business controls the cortisol regulation niche through unique patents that make switching therapies difficult. Corcept Therapeutics (CORT) is currently expanding its scientific research, adapting its developments to combat cancer and other critical pathologies.

Corcept Therapeutics Inc. (CORT): Long-Term Debt to Equity from 07/04/2022 to 10/30/2026

Comprehensive metric breakdowns and analytics for Corcept Therapeutics (CORT)

- stock price and consensus target price:
Quote Chart Corcept Therapeutics Inc.|CORT - Analyst Consensus Forecast
- market capitalization indicators:
Market Value Corcept Therapeutics Incorporated|CORT - Enterprise Value
- balance sheet net asset value indicators:
Book Value per Share Corcept Therapeutics|CORT - Company Book Value|Market Value to Book Value corcept.com|CORT - Aggregate Company Assets
- debt and solvency information:
Total Debt to Equity Ratio Corcept Therapeutics|CORT - Long-Term Debt to Capital|Short-Term Debt to Capital corcept.com|CORT - Company Total Debt|Debt to Net Assets Ratio Corcept Therapeutics Incorporated|CORT - Company Long-Term Debt|Company Current Liabilities Corcept Therapeutics|Immediate Liquidity corcept.com
- net income and valuation ratios data:
CORT - Net Income
General company analysis:Corcept Therapeutics Inc. - CORT
Signature product of Corcept Therapeutics

This indicator is calculated as the ratio of accounts payable with a maturity of more than one year to total equity, reflecting the business's degree of dependence on long-term debt financing. The stable cash flow from the sale of endocrine drugs by Corcept Therapeutics (CORT) allows for the effective management of this leverage, which is clearly demonstrated by the ratio of long-term loans to equity.

Analysis of competing companies

Ascendis Pharma AS - Long-Term Liabilities to Equity|Long-Term Debt to Capital MDGL|RYTM (Rhythm Corp) - Long-Term Debt to Capital Coefficient|Long-Term Debt to Capital AKRO (Akero Therapeutics)|Long-Term Debt to Capital metsera.com MTSR|MLTX - Long-Term Debt to Equity|Long-Term Debt to Capital Coefficient CRNX (Crinetics Pharmaceuticals, Inc.)|NewAmsterdam Pharma N.V. (NAMS) - Long-Term Debt to Equity|Long-Term Debt to Equity Ratio Soleno Therapeutics Corp|FOLD (Amicus Therapeutics) - Long-Term Debt to Capital|Long-Term Debt to Capital 89bio.com|Long-Term Debt to Equity Ratio AGIO (Agios Pharmaceuticals, Inc.)|GPCR (Structure Therapeutics Inc) - Long-Term Debt to Capital Coefficient|Long-Term Debt to Equity MiMedx Group MDXG|RZLT - Long-Term Debt to Equity Ratio|Lexicon Pharmaceuticals - Long-Term Debt to Capital|Long-Term Liabilities to Capital mbxbio.com|ALT (Altimmune) - Long-Term Debt to Equity Ratio|AARD: Long-Term Loans to Capital Ratio|SGMT (Sagimet) - Long-Term Debt to Capital|Long-Term Debt to Capital BioAge Labs, Inc|Long-Term Debt to Capital BMEA|Long-Term Debt to Equity QNCX (quincetx.com)|Long-Term Debt to Equity Fractyl Health GUTS|vTv Therapeutics, Inc. (VTVT) - Long-Term Liabilities to Capital|ATPC - Long-Term Debt to Equity|PLUR: Long-Term Debt to Equity|SYBX: Long-Term Debt to Capital|LPCN - Ratio of Long-Term Indebtedness to Capital|Long-Term Debt to Equity Matinas BioPharma Holdings, Inc.|Spruce Biosciences Inc. (SPRB) - Ratio of Long-Term Indebtedness to Capital|Long-Term Debt to Equity Galecto Corp (GLTO)|Long-Term Debt to Equity Ratio Carmell Therapeutics CTCX|Long-Term Debt to Capital LUMO (Lumos Pharma, Inc.)|ONVO - Long-Term Debt to Equity Ratio|RDUS - Long-Term Debt to Equity